We have identified a novel human septin family gene Bradeion, which is specifically expressed in human colorectal cancer and malignant melanoma. In order to analyze the implications of tumor -specific gene expression, ribozymes and its derivatives were specifically designed and transfected into various colorectal adenocarcinoma cell lines for Bradeion inactivation. We constructed ribozyme expression plasmids controlled by a human tRNA
C olorectal tumorigenesis is commonly believed to involve typically about five genetic mutations (or hits ) of both proto -oncogenes ( such as ras ) and tumorsuppressor genes (such as p53, DCC, and APC ). 2, 3 Therefore, it is far from obvious which of these genetic defects should be targeted for correction in a gene therapy approach. It also seems improbable that, even if a single mutation could be corrected in every tumor cell, the malignant phenotype would necessarily be reversed because the evolution of malignancy in human tumors is a multicomponent event. 2 Therefore, desired gene targets for the monitoring and controlling of cancer might have the following features: (a ) selectivity of cell types, (b ) specificity (''all or none'' type expression changes ), and, more importantly, (c ) neither any amino acid nor structural change caused by point mutations, deletions, missense mutation, etc., in the course of phenotype change. Currently, there have been reported few genes or proteins that satisfy these categories, and it is supposed that these candidate genes do not have to be closely involved in the process of tumorigenicity. For example, most of the target molecules of anticancer drugs and the common tumor markers are not specifically oncogene products nor molecular chaperones related to the process of carcinogenesis.
We have initiated an approach to identify and characterize key molecules described above and, for this purpose, constructed cDNA libraries from senescent and immortal cells. 4 Human brain and heart cDNA libraries were also used to identify the novel molecules related to cell cycle regulation and termination. Through these processes, we have identified a variety of novel genes, and one of these is Bradeion. 1 The Bradeion gene belongs to the mammalian septin family genes, 5 and originally was discovered from human brain cDNA by expression screening using the monoclonal antibody CE5. 6 Interestingly, Bradeion is expressed specifically in two human cancers, colorectal cancer and malignant melanoma, with ''all or none'' expression profile and no point mutations.
1 These characteristics indicate that normal function of Bradeion is likely required for necessary functions of colorectal adenocarcinoma cells and that Bradeion may be a useful target for therapy.
We have then proceeded to develop efficient Bradeion gene -inactivating agents using antisense ribozymes. 7 -9 We have demonstrated that ribozymes targeting Bradeion transcripts are capable of specific -cleaving its target in vitro, and stable transfectants of ribozyme -transformed colorectal adenocarcinoma cells exhibited reduced cell growth and G2 arrest. The present study thus extends the utility of these hammerhead ribozymes and its derivative tools based on the function of Bradeion for target validation in monitoring and controlling the colorectal cancer in vivo. It is emphasized that a novel gene Bradeion provides a practical tool to target the colorectal cancer by disruption of cell proliferation and cell cycle regulation.
Materials and methods

Design of tRNA
Val -embedded ribozymes
Ribozymes used in the present study were constructed according to the methods as described. 9 -11 The target sequences of these ribozymes specific for Bradeion mRNA are the following: Brad-1: nucleotides 569-583 of Bradeion clone; Brad-2: nucleotides 588 -602; Brad-3: nucleotides 595 -609; Brad -4: nucleotides 699 -713. The target sequences of the ribozyme specific for Bradeion mRNA are the following: Brad -1: nucleotides 108-122 of Bradeion clone; Brad-2: nucleotides 157 -171; Brad-3: nucleotides 304-318, Brad -4: nucleotides 378 -392.
Cells, transfection, and cell cycle analysis
Human colorectal adenocarcinoma cell lines (SW480, COLO201, DLD -1, HT-29, LoVo, LS174T, SK -CO -1, SW620, SW948, SW1417 ) were obtained from ATCC ( American Type Culture Collection, Manassas, VA ) and cultured in the media recommended for each cell line. 3, 12 The cell lines used as negative controls were HeLa and K562 cells lines -the same cell lines which appear in the MTN 2 blots provided by Clontech ( Palo Alto, CA ). 1 After the serial gene expression analysis of those cell lines, SW480 was chosen for further transfection experiments. SW480 was cultured in Leibovitz' L -15 medium supplemented with 10% fetal bovine serum. 12 Transfections were carried out with the SuperFect Transfection Reagent ( Qiagen, Valencia, CA ), as recommended by the manufacturer. Ribozyme -transfected cells were selected by incubation with G418, and ribozyme derivatives-transfected cells were selected with G418 (500 g/ mL media) and hygromycin B (250 g/ mL media ) ( Invitrogen, Carlsbad, CA ) for more than 4 weeks. As controls, inactive ribozymes and derivatives were transfected and selected as described above. The doubling time of each cell line was examined and determined as described. 8, 9 For flow cytometry analysis, cells were pelleted and resuspended in 1 mL of PBS containing 2 g /mL RNase and 50 mg / mL propidium iodide, and incubated for more than 30 minutes at 378C. The profile of cells in the G0 /G1, S, and G2 /M phases of the cell cycle was analyzed by using EPICS ELITE ESP ( Beckman Instruments, Fullerton, CA ) according to the instructions by manufacturers.
Detection of Bradeion genes by reverse transcription polymerase chain reaction ( RT -PCR )
Total cellular RNA was isolated from the cultured cell lines using Gibco/ BRL TRIzol reagent (Invitrogen, Carlsbad, CA ). For RT-PCR of both Bradeion genes, RT of 5 g of total RNA was primed at 458C for 30 minutes using SuperScript One -Step RT-PCR System (Invitrogen, Carlsbad, CA ), and the reaction mixture was directly used for PCR. Four primer pairs were synthesized based on the sequence of Bradeion gene 1 and used for PCR amplification. PCR was performed as described previously, 1 and the resulting RT-PCR products were subject to gel electrophoresis in 12.5% GeneGel by GenePhor system ( Amersham Biosciences Corp, Piscataway, NJ ). The sequences of RT-PCR products were confirmed by direct sequencing.
Growth of colon cancer xenografts in athymic mice
The stable transformants and parental cell line ( SW480; 5Â10 5 cells ) were subcutaneously inoculated into nude mice ( n =10 for each transformant and the parental cell line, female, 8 weeks, BALB /cA -nu; Clea Japan, Tokyo, Japan ). The growth rates of the cells were estimated by measuring the size of tumor lesions after inoculation. The size was calculated by the equation, V=1/2AB 2 , in which A and B are the experimental measurements in millimeters of length and width, respectively. All experiments on laboratory animals were performed in accordance with the care and use guidelines of the Central Institute for Experimental Animals, Kawasaki, Japan. 8 
Results
Design of tRNA
Val -driven antisense ribozymes
In order to evaluate the tumor-specific expression of Bradeion and , we constructed ribozyme expression plasmids controlled by a human tRNA Val promoter, which targeted the Bradeion transcripts. The ribozyme transcripts by this pol III -dependent expression system are much higher than that of pol II expression system. 10, 11 The target sequences of these ribozymes and maxizymes in Bradeion mRNA are shown in Figure 1 , A and B, and selected cleavage sites are indicated by black boxes.
As for targeting of Bradeion , it was not possible to cleave by the conventional ribozyme specifically the Bradeion mRNA without damaging the Bradeion mRNA. Therefore, we utilized the recently created ''maxizyme,'' which has an allosterically controllable function. 11 This allosteric form consists of two substrate binding arms and catalytic core region, and would have a cleavage activity only when the two substrate binding arms of the maxizyme interact with the Bradeion mRNA. In addition, pol IIIdependent expression system enables both ribozyme and maxizyme transcripts to be exported to the cytoplasm, which resulted in the presence of ribozymes and their target mRNA within the same cellular compartment. This phenomenon would resemble the changes in conformation of allosteric proteinaceous enzymes that occur in response to their effector molecules. The maxizyme construction with the target candidate sequences in expression plasmids was shown in Figure 1C , and the heterodimeric structure was shown in Figure 1D .
These ribozyme and/or maxizyme expression plasmids were transfected into SW480 cells. This cell line has mutated p21 and APC, and wild -type ( WT ) p53.
3 Several independent stable cell lines were generated by G418 (500 g/mL media ) or hygromycin selection (250 g/mL media).
Growth inhibition and disruption of cell division by the cleavage of anti -Bradeion mRNA
Bradeion -and -specific ribozymes were transfected into the SW480 cells ( Fig 1A ) . Stably transfected SW480 cells that harbored a ribozyme and /or maxizyme were selected by G418 (ribozyme and maxizyme ) and hygromycin (maxizyme ). 10, 11 A total of 66 independent lines for each mutant ( Bradeion single mutant, Bradeion single mutant, and
Bradeion and double mutant ) were generated by limit dilution method in 96 titer well dishes. Using 47 among 67 selected cell lines, we examined the functional significance of the ribozyme and maxizyme in the regulation of cell cycle and cell division in those selected cell lines. The parameters used were the doubling time, cell cycle analysis, and RT-PCR of Bradeion genes. 8, 9 Inactive ribozyme and maxizyme transfected cells were used as controls. Those ribozymes differed from the active ribozymes by a single G5 -to -A5 mutation in the catalytic core. 2 ) showed the WT phenotype of cell population in each phase (G0 / G1, S, and G2 /M), with up to 70% cell population at G0 /G1 phase (2n ) and 15% at G2 /M phase ( 4n). Cells with inactive maxizymes demonstrated the similar phenotype with normal cell population ( unpublished data ). In contrast, Bradeion single mutant cells showed irrelevant late S clusters in cell cycle (Fig 2A, lane 3 ) . The same late S clusters were observed in Bradeion single mutant cells, too ( Fig 2A,  lane 4 ) .
In contrast, the cells with Brad or ribozymes showed irreverent late S clusters in cell cycle (Fig 2B, lanes 3 and 4) . The transformants with Brad and ribozymes showed significantly different phenotype, with slower cell growth ( over 300 hours doubling time compared to 20-24 hours doubling time of control SW480 cells and the cell transfected with inactive ribozyme ). Flow cytometry analysis demonstrated 8n peak (8 -12% population) with increased cell Figure 2A ) showed second G1 peak, which indicates the disruption of chromosomes. The cell population in arrested G2 /M phase and 8n peak varies slightly among the cell lines of double mutants; however, the phenotype was similar in all double mutant cell lines.
Ribozyme -mediated suppression on Bradeion a and b
To examine levels of both Bradeion and mRNA, we performed RT-PCR analysis. As shown in Figure 2B 5 -9 ) .
Interestingly, Bradeion mRNA in the stable transformants so far remained positive in all the clones used in the present study ( lanes 3 -9 ) . The level of expression varied among clones; however, it could be detected in both Bradeion -specific mutants and double mutants. In double mutant cells (lanes 5 -9 ), both levels of Bradeion and mRNA were significantly decreased compared with WT ( lane 1 ) and inactive ribozyme expressing SW480 cells ( lane 2 ).
Loss of tumorigenesis shown by ribozyme -transfected cancer cell lines in athymic mice
Heterotrophic transplantation of the SW480 cells as xenografts in athymic nude mice resulted in the rapid development of progressive tumor nodules ( Fig 3 ) . Bradeion -specific ribozymes significantly suppressed tumor growth of SW480 cells in mice. At 60 days after transplantation, tumors with Bradeion -and -specific ribozymes were 32.4% and 25.9%, respectively, of the control tumors in a volume. Transfection of both Bradeion and ribozymes more significantly suppressed tumor growth in the mice system, i.e., tumors with both Bradeion and ribozymes were 10.5% (Brad -3+3) and 4.3% ( Brad -4+3) compared with the controls in a volume. The results were compatible with those of flow cytometric and RT-PCR analyses ( Figures 2B and 3 ) . These results were 
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Impaired Bradeion expression in colorectal cancer M Tanaka et al not observed when the SW480 and other colorectal adenocarcinoma cell lines were used (unpublished data ).
Discussion
The results obtained here could point out the essential role of a novel human septin family gene Bradeion for the proliferation and growth of colorectal cancer cells. We described the construction of the hammerhead ribozyme specifically targeting Bradeion and transcripts. This ribozyme expression plasmid controlled by a human tRNA Val promoter, together with the application of its allosteric form ''heterodimeric maxizyme,'' was so far successfully applied and capable of specific -cleaving the target in vitro in the present study. Stable transformants expressing the ribozymes altered morphology and reduced cell growth in the cultured cell system. The flow cytometry analysis demonstrated that the transformants with both Brad and ribozymes showed significant growth inhibition by causing G2 arrest. In vivo mice studies demonstrated marked tumor growth suppression by the Bradeion -specific ribozymes, which was compatible with results of flow cytometric and RT-PCR analyses.
Bradeion belongs to the septin family genes, 5 which are evolutionarily conserved cytoskeletal GTPases involved in cytokinesis and other cellular processes. The best conserved region is an ATP /GTP binding site ( P-loop ), called Walker's A box. 13, 14 The expression is detected only in colorectal cancer and malignant melanoma, and not found in other cancers such as stomach cancer and lung cancer. This unique expression profile has never been observed among other mammalian septin family genes. 1 For further analysis of this novel gene, we first tried to overexpress pEGFP ( Enhanced Green Fluorescent Protein; Clontech ) Bradeion. However, the massive aggregate formation in cytoplasm was observed when EGFP -fused Bradeion was expressed, which caused apoptotic cell death until 24 hours after transfection ( M Tanaka, unpublished data ). These results were not informative to know the further cellular function of Bradeion gene, and instead, we decided to disrupt Bradeion expression. With the advent of the development of hammerhead ribozymes and its derivatives reported by our institute, 10, 11 the Bradeion mRNA containing a characteristic exonexon junction can be specifically targeted and cleaved without damaging a related Bradeion mRNA. Based on the results obtained using ras -inactivating ribozymes by Kijima et al, 7 Yamazaki et al, 8 and Tsuchida et al, 9 we succeeded in constructing and using Bradeion -and -specific ribozymes.
The present study demonstrated that the impaired expression of Bradeion and directly affected cell division. There are wide variances in cell cycle disorders among cell lines, which may be caused by the variation of the inhibition rates in Bradeion expression. The specific expression of ribozyme and maxizyme transfected was confirmed in each procedure. More importantly, the persistence of slight Bradeion expression even in double mutants will suggest that Bradeion expression might be essential for the maintenance and proliferation of colorectal adenocarcinoma cells. It is emphasized that the partial decrease of Bradeion expression was enough to cause growth inhibition and arrest in colorectal carcinoma cells.
The data obtained here extend the utility of these tools for target validation in monitoring and controlling colorectal cancer. The genetic variance among individuals indeed prevents many candidate genes from being used as a target for gene therapy. 2 For example, mutated p53 were identified among 30 -50% of the patients, and the same ratio was observed for p21 mutations. 15 -17 However, the value of the genes for therapy remains unclear, and further advances in the gene transfer field will likely be required to advance ribozymes as a therapeutic agent. 2 Indeed, as potential therapeutics, several problems remain to be solved related to delivery, specificity, and expression. We have also been trying to solve this problem using a recombinant adenovirus as a tool for delivery. 7 -9 Thus, the preset study indicates the possible efficacy of Bradeion ribozymes to disrupt cell proliferation and division. A recent report describes that the P -loop structure of septins is closely related to the induction of apoptosis. 18 Bradeion also triggers apoptotic processes by overexpression in cancer cell ( M Tanaka, unpublished data ). More information related to specific killing of cancer cells is being examined to demonstrate the biochemical function and signal transduction mechanisms related to Bradeion expression.
It is clear, however, that the data demonstrated here clearly highlight the clinical potential importance of the Bradeion gene as a tumor-specific target. Further laboratory and clinical investigations may provide novel strategies for the diagnosis and therapy of colon cancer.
